Schizophrenia
LB Pharma’s Phase II Success Revives Promising Antipsychotic Class for US Patients with Schizophrenia
LB-102, schizophrenia, Phase II trial, antipsychotic, benzamide class
LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia in US
LB-102, schizophrenia, Phase 2 trial, benzamide antipsychotic, efficacy, safety
LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial
LB-102, Benzamide antipsychotic, Schizophrenia treatment, Phase II clinical trial, PANSS score reduction, First-in-class potential
LB-102: Promising Phase 2 Results Revive Benzamide Antipsychotics for Schizophrenia Treatment in the US
LB-102, schizophrenia, benzamide antipsychotics, Phase 2 trial, PANSS scores, safety profile, once-daily dosing
Cobenfy: A Breakthrough in Schizophrenia Treatment with a Novel Mechanism of Action
Cobenfy, schizophrenia, muscarinic receptors, xanomeline, trospium chloride, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, antipsychotic drugs.
Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment
Brilaroxazine, Schizophrenia treatment, Antipsychotic medication, Efficacy and safety, Long-term treatment, Negative symptoms, Cognitive functioning
AbbVie’s Schizophrenia Drug Fails in Phase II Trials, Casting Doubt on Neuroscience Strategy
AbbVie, schizophrenia, emraclidine, Phase II trials, Cerevel Therapeutics, neuroscience strategy, pharmaceutical industry
Bristol Myers Squibb’s $14 Billion Bet Pays Off: FDA Approves Novel Schizophrenia Drug Cobenfy
Bristol Myers Squibb, Karuna Therapeutics, FDA approval, schizophrenia, Cobenfy, novel treatment, muscarinic receptor, psychiatric medication
BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis
KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.
Neurocrine Biosciences Advances Schizophrenia Treatment with Positive Phase 2 Data for NBI-1117568
Neurocrine Biosciences, schizophrenia, NBI-1117568, Phase 2 data, Phase 3 advancement, muscarinic M4 selective acetylcholine receptor agonist